ATR and WEE1 Inhibitors After PARP Resistance: Emerging DNA Damage Response Strategies Across Solid Tumors Review Abstract Background Resistance to poly(ADP-ribose) polymerase (PARP) inhibition has intensified interest in other components of the DNA damage response and replication-stress network. Early clinical studies have evaluated ataxia telangiectasia
Oncology
Skin Cancer Detection and Procedural Decisions in Family Practice: When to Biopsy, Use Cryotherapy, or Refer
Skin Cancer Detection and Procedural Decisions in Family Practice: When to Biopsy, Use Cryotherapy, or Refer Review Abstract Background Evaluation of an identified suspicious skin lesion is fundamentally distinct from routine skin cancer screening. The U.S. Preventive Services Task Force (USPSTF) concludes that evidence is insufficient to
Melanoma Screening in the AI Era: Why Dermatologists Remain the Clinical Standard and AI Should Stay an Adjunct
Melanoma Screening in the AI Era: Why Dermatologists Remain the Clinical Standard and AI Should Stay an Adjunct Review Abstract Purpose: Melanoma remains one of the most aggressive forms of skin cancer, accounting for a disproportionate number of skin cancer related deaths despite representing a relatively small
BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study
BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study Review Abstract Purpose: This review assesses the rationale, emerging clinical evidence, safety considerations, and practical implications of Bruton tyrosine kinase (BTK) degraders in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), particularly after
Can Bispecific Antibodies Move Safely Into the Outpatient Clinic? A Label-Concordant Framework for Clinicians
Can Bispecific Antibodies Move Safely Into the Outpatient Clinic? A Label-Concordant Framework for Clinicians Review Abstract Purpose: This review assesses whether CD3-engaging bispecific antibody therapy can be delivered safely in outpatient oncology settings, with emphasis on cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infection prevention,
Menin Inhibitors in AML: Targeting KMT2A-Rearranged and NPM1-Mutated Disease
Menin Inhibitors in AML: Targeting KMT2A-Rearranged and NPM1-Mutated Disease Review Abstract Purpose Acute myeloid leukemia (AML) is a heterogeneous group of hematologic malignancies defined increasingly by recurrent molecular and cytogenetic abnormalities. KMT2A rearrangements and NPM1 mutations identify biologically distinct leukemias that frequently rely on menin-dependent
Cytokine Release Syndrome 2.0: Managing Immune-Effector Toxicity as Cell Therapy Moves Earlier, Broader, and Beyond CAR T
Cytokine Release Syndrome 2.0: Managing Immune-Effector Toxicity as Cell Therapy Moves Earlier, Broader, and Beyond CAR T Review Abstract Purpose: This article reviews cytokine release syndrome (CRS) and related immune-effector toxicities in the expanding era of cellular therapy, with emphasis on practical recognition, risk stratification,
Fluorescence-Guided Surgery: From Indocyanine Green to Tumor-Specific Fluorophores in 2026
Fluorescence-Guided Surgery: From Indocyanine Green to Tumor-Specific Fluorophores in 2026 Review Key Takeaways Fluorescence-guided surgery (FGS) is reshaping oncologic surgery by enabling real-time molecular visualization of tumors and critical anatomical structures. The field has evolved from non-specific fluorescent dyes toward highly targeted fluorophores capable of identifying malignant
Post-Polypectomy Surveillance: Are We Over-Scoping Patients (and Under-Scoping the High-Risk Ones)?
Post-Polypectomy Surveillance: Are We Over-Scoping Patients (and Under-Scoping the High-Risk Ones)? Review Key Takeaways Post polypectomy surveillance is a critical component of colorectal cancer prevention strategies, aimed at reducing the incidence of interval colorectal cancers through timely follow up colonoscopy after adenoma removal. However, current surveillance practices
Thrombosis and Cancer Immunotherapy: The Next Frontier of Thromboinflammation
Thrombosis and Cancer Immunotherapy The Next Frontier of Thromboinflammation Review Abstract Cancer immunotherapy has fundamentally transformed the treatment landscape across multiple malignancies, offering durable responses and prolonged survival in patients with previously limited therapeutic options. Immune checkpoint inhibitors, chimeric antigen receptor T cell therapies, bispecific antibodies,
